| http://www.w3.org/ns/prov#value | - During fourth quarter 2014, Newron plans to initiate a placebo-controlled safety and efficacy trial in schizophrenic patients who are poor responders to current treatment.??? Marco Caremi, Newron???s Executive VP BD, added: ???In 2013, Newron was granted the composition of matter patent on NW-3509 in the US. The patent has also been granted in other territories including Japan.
|
